These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25823806)

  • 1. The use of EEG parameters as predictors of drug effects on cognition.
    Blokland A; Prickaerts J; van Duinen M; Sambeth A
    Eur J Pharmacol; 2015 Jul; 759():163-8. PubMed ID: 25823806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice.
    Featherstone RE; Liang Y; Saunders JA; Tatard-Leitman VM; Ehrlichman RS; Siegel SJ
    Neurobiol Dis; 2012 Sep; 47(3):338-46. PubMed ID: 22627142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
    Ahnaou A; Huysmans H; Jacobs T; Drinkenburg WH
    Neuropharmacology; 2014 Nov; 86():362-77. PubMed ID: 25181033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declarative memory.
    Riedel WJ; Blokland A
    Handb Exp Pharmacol; 2015; 228():215-36. PubMed ID: 25977084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal paradigms to assess cognition with translation to humans.
    Wallace TL; Ballard TM; Glavis-Bloom C
    Handb Exp Pharmacol; 2015; 228():27-57. PubMed ID: 25977079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The influence of pyrithioxin on acute alcohol-contingent changes in the EEG, evoked potentials and behavior of cats].
    Dolce G
    Act Nerv Super (Praha); 1974 Mar; 16(1):42-4. PubMed ID: 4454935
    [No Abstract]   [Full Text] [Related]  

  • 7. Signaling pathways relevant to cognition-enhancing drug targets.
    Ménard C; Gaudreau P; Quirion R
    Handb Exp Pharmacol; 2015; 228():59-98. PubMed ID: 25977080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined neuropsychological and neurophysiological assessment of drug effects on groups and individuals.
    Gevins A; Ilan AB; Jiang A; Sam-Vargas L; Baum C; Chan CS
    J Psychopharmacol; 2011 Aug; 25(8):1062-75. PubMed ID: 21106606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of anticholinergic drugs, chlorpromazine and LSD-25 on evoked potentials, EEG and behaviour.
    Green DM; Aldous FA
    Prog Brain Res; 1972; 36():143-58. PubMed ID: 4644024
    [No Abstract]   [Full Text] [Related]  

  • 10. EEG biomarkers of target engagement, therapeutic effect, and disease process.
    Featherstone RE; McMullen MF; Ward KR; Bang J; Xiao J; Siegel SJ
    Ann N Y Acad Sci; 2015 May; 1344():12-26. PubMed ID: 25823856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyzing event-related EEG data with multivariate autoregressive parameters.
    Schlögl A; Supp G
    Prog Brain Res; 2006; 159():135-47. PubMed ID: 17071228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cognitive brain functions in caffeine users: a P3 evoked potential study.
    Dixit A; Vaney N; Tandon OP
    Indian J Physiol Pharmacol; 2006; 50(2):175-80. PubMed ID: 17051738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of non-human primates in central nervous system safety pharmacology.
    Porsolt RD
    J Pharmacol Toxicol Methods; 2013; 68(1):23-9. PubMed ID: 23518064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaco-EEG Studies in Animals: An Overview of Contemporary Translational Applications.
    Drinkenburg WH; Ruigt GS; Ahnaou A
    Neuropsychobiology; 2015; 72(3-4):151-64. PubMed ID: 26901596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the cerebral activity by time-frequency representation of evoked EEG potentials.
    Clariá F; Vallverdú M; Riba J; Romero S; Barbanoj MJ; Caminal P
    Physiol Meas; 2011 Aug; 32(8):1327-46. PubMed ID: 21765206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EEG investigations in cognitive impairments].
    Szirmai I; Kamondi A
    Ideggyogy Sz; 2011 Jan; 64(1-2):14-23. PubMed ID: 21428034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical research into cognition enhancers.
    Sarter M
    Trends Pharmacol Sci; 2006 Nov; 27(11):602-8. PubMed ID: 16997388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine Stroop and addiction memory--an ERP study.
    Fehr T; Wiedenmann P; Herrmann M
    Int J Psychophysiol; 2006 Nov; 62(2):224-32. PubMed ID: 16492391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate.
    Smith ME; Gevins A; McEvoy LK; Meador KJ; Ray PG; Gilliam F
    Epilepsia; 2006 Apr; 47(4):695-703. PubMed ID: 16650135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.